1.Determination of Two Andrographolide Derivatives in Andrographolide Sulfonates by UPLC
Yanhong LIU ; Fan CHENG ; Difa LIU ; Xiaoling YANG
China Pharmacist 2014;(11):1833-1834,1835
Objective:To establish an UPLC method for the simultaneous determination of andrographolide sulfonate E and an-drographolide sulfonate F in andrographolide sulfonates. Methods: The sample was separated on a Shimadzu Shim-pack XR-ODSⅢcolumn (2. 0 m × 75 mm, 1. 6 μm) with acetonitrile( A) and potassium dihydrogen phosphate buffer solution( B:1. 361 g potassium dihydrogen phosphate and 1. 0g heptane-1-sodium sulfonate were dissolved in 1 000 ml water) as the mobile phase with gradient elu-tion, and the flow rate was 0. 4 ml·min-1 ,the column temperature was 30℃, and the detection wavelength was set at 225nm. Re-sults:The linear range of andrographolide sulfonate E was 4. 39-43. 88μg·ml-1(r=1. 000 0) and the average recovery was 98. 71%(RSD=1. 41%, n=6). The linear range of andrographolide sulfonate F was 4. 43-44. 32 g·ml-1(r=1. 000 0) and the average re-covery was 99. 29%(RSD=0. 76%, n=6). Conclusion:The method is reproducible, sensitive and accurate, which can be used in the quality control of andrographolide sulfonates.
2.The comparison of efficacy between GP and NP regimens in the treatment of advanced non-small cell lung cancer.
Luwen TIAN ; Zhiming WANG ; Difa LIU
Chinese Journal of Lung Cancer 2002;5(6):432-434
BACKGROUNDTo evaluate the clinical efficacy and toxicity of GP (gemcitabine+cisplatin) and NP (navelbine+cisplatin) regimens in the treatment of advanced non-small cell lung cancer (NSCLC).
METHODSSeventy-six cases of advanced NSCLC were enrolled. Among them, 36 received GP (gemcitabine 1.0 g/m² D1,8,15+cisplatin 30 mg/m² D1-3), meanwhile 40 were administrated NP regimen (navelbine 30 mg/m² D1,8+cisplatin 30 mg/m² D1-3).
RESULTSThe overall response rates of GP and NP were 52.8% and 47.5% respectively (P > 0.05), and the median survivals were 9.8 and 8.7 months respectively (P > 0.05). The main toxicity was hematological toxicity. The incidences of leukopenia were 58.3% and 92.5% in GP and NP respectively (P < 0.01), and those of grade III-IV leukopenia were 16.7% and 52.5% respectively (P < 0.01 ). There was no significant difference in thrombocytopenia incidence between the two groups, however, GP group had a remarkably higher incidence of grade III-IV thrombocytopenia (33.3%) than NP group ( 10.0% ) (P < 0.05 ).
CONCLUSIONSEfficacy of GP regimen is similar to that of NP and both of them can be well tolerated by patients.
Result Analysis
Print
Save
E-mail